The biotech IPO wave keeps rolling. Parabilis Medicines set terms for an IPO of up to $475 million, which would rank as the year’s second-largest new biotech stock offering behind Kailera’s $625 million debut in April. Parabilis is the same company that signed a Regeneron partnership last month for Antibody-Helicon Conjugates, a novel therapeutic class. The company raised more than $700 million in private funding before filing, making it the fifth biotech to IPO in 2026 after exceeding that private funding threshold. Total 2026 biotech IPO proceeds already surpass $3.2 billion. Meanwhile, Roche chairman Severin Schwan called U.S. tariff policies “blackmail”—the most direct public criticism of the tariff framework by a sitting major pharma executive this year. Alnylam signed an AI collaboration with Inceptive Nucleics to accelerate RNAi discovery. And BioSpace reported that Chinese biotechs are no longer a “bargain pool” for Western pharma—deal dynamics are changing fast, with Chinese companies commanding higher upfront payments as the quality of their clinical data reaches global standards.
Top Story: Parabilis IPO Terms Signal the IPO Window Remains Wide Open
What Happened: Parabilis Medicines set terms for an IPO that would raise as much as $475 million. BioPharma Dive reported it would rank as the year’s second-largest new biotech stock offering behind Kailera’s $625 million debut.
What Parabilis Is Building
Parabilis is developing Antibody-Helicon Conjugates (AHCs), a novel therapeutic class that the company signed a strategic research collaboration with Regeneron to advance last month. AHCs represent a new modality in the antibody-conjugate landscape that has been one of the hottest areas in oncology throughout 2026. With Enhertu and Datroway approved in early-stage settings, sac-TMT producing two Phase 3 wins for Merck, and EV-304 showing 55.8% pathologic complete response in bladder cancer, the appetite for novel conjugate approaches has never been stronger.
Having a Regeneron partnership in hand before the IPO changes the risk profile for public market investors. Regeneron’s clinical and commercial infrastructure validates the AHC platform—the partnership signals that a sophisticated pharma partner evaluated the science and committed resources. For IPO investors, this is a meaningful de-risking factor that distinguishes Parabilis from typical early-stage biotech debuts.
The Broader IPO Signal
The Parabilis terms carry significance beyond the individual company. The biotech IPO market has produced more than $3.2 billion in total proceeds in 2026. BioPharma Dive noted Parabilis would be the fifth biotech to IPO after raising $700 million or more in private funding—a threshold that was nearly unheard of before 2025. These are not scrappy startups testing the public markets with minimal data. They are well-capitalized companies with validated platforms and, increasingly, existing pharma partnerships.
The health of the IPO window matters for the entire biotech ecosystem. When the IPO market is open, private biotech companies have a path to liquidity that supports continued venture investment, which in turn funds the early-stage research that produces the acquisition targets the large pharma companies need to fill their pipeline gaps. The $106 billion M&A cycle we reported last week depends on a steady supply of clinical-stage assets, and those assets depend on a functioning capital market that rewards innovation. The Parabilis terms suggest that capital market is functioning well.
Roche Chairman Calls U.S. Tariffs “Blackmail”
What Happened: Roche chairman Severin Schwan called U.S. tariff policies “blackmail” and described protectionism by the United States and China as the company’s biggest geopolitical concern, according to Reuters via Endpoints News. Schwan was specifically asked about the MFN agreement Roche/Genentech signed with the Trump administration.
Why This Comment Matters
Schwan’s remarks are the most direct public criticism of U.S. pharma tariff policy by a sitting major pharmaceutical executive this year. All 17 targeted companies have signed MFN deals with the administration. The deals commit companies to lower U.S. drug prices toward international reference benchmarks in exchange for tariff exemptions. Until now, pharmaceutical executives have been carefully diplomatic about the framework—publicly praising their investments and partnerships while privately expressing concerns about the precedent.
Schwan broke that diplomatic silence. By describing the MFN agreement as being signed under “blackmail,” he is saying publicly what many in the industry have said privately: the deals were made under duress, not voluntarily. The tariff framework creates a choice between signing an MFN deal (which compresses pricing and margins) and facing tariffs (which increase costs and disrupt supply chains). Neither option is attractive. Companies signed because the alternative was worse, not because they agreed with the policy.
The “blackmail” characterization also signals growing frustration among European pharma executives specifically. European companies face a dual squeeze: U.S. tariffs and MFN pricing on one side, and European pricing reforms on the other (as illustrated by Lilly and Boehringer each pulling $1 billion-plus from Germany last week). The policy environment on both sides of the Atlantic is compressing margins simultaneously, and Schwan is the first to say it bluntly in a public forum.
His candor may have consequences. Other executives may be emboldened to speak more directly about a framework they view as coercive. Alternatively, the administration could view the comments as an invitation to scrutinize Roche’s compliance with its MFN commitments or to use Roche as an example if it pushes back against the terms. Either way, the “blackmail” remark will be referenced in every subsequent discussion about the MFN framework’s legitimacy and staying power.
The broader context is the dual pricing squeeze that European pharma companies face. On one side, U.S. tariffs and MFN pricing compress the world’s most profitable pharmaceutical market. On the other, European healthcare reforms (Germany’s pricing initiative, which prompted Lilly and Boehringer to pull $1 billion-plus each last week) are compressing the home market. European pharmaceutical companies are caught between two governments simultaneously tightening the pricing environment from opposite directions. Schwan’s frustration is not just about tariffs—it is about the shrinking geography of favorable pricing that funds the R&D investment the entire industry depends on.
Alnylam Partners with Inceptive on AI for RNAi Discovery
What Happened: Alnylam Pharmaceuticals signed a strategic AI collaboration with Inceptive Nucleics to accelerate the discovery of RNA interference therapies under its Alnylam 2030 strategy.
How AI Is Being Applied Differently Across Pharma
Inceptive’s AI platform helps optimize siRNA sequence design and selection, potentially accelerating the identification of lead candidates from Alnylam’s pipeline targets. The application is specific to RNAi therapeutics: designing the optimal short interfering RNA sequence that will silence a target gene requires evaluating millions of possible sequences for potency, specificity, stability, and deliverability. AI can compress that evaluation from months of wet-lab work to days of computational analysis.
This adds to the growing AI drug discovery ecosystem, but the Alnylam/Inceptive deal underscores that AI adoption in pharma is not monolithic. Different platforms serve fundamentally different needs. Anthropic’s Claude (partnered with BMS, Sanofi, Novo, AbbVie, Novartis) provides broad AI capability across drug development workflows. Isomorphic Labs ($2.7 billion in funding, partnered with Lilly and Novartis) focuses on protein structure prediction and molecular design. Profluent (Lilly, $2.25 billion collaboration) uses AI to design recombinases for gene editing. And now Inceptive (Alnylam) optimizes RNA sequences for RNAi therapeutics.
The companies deploying AI most effectively are matching the right platform to the right problem rather than treating AI as a generic accelerant. Alnylam’s choice of an RNA-specific AI partner reflects this targeted approach. The company’s Alnylam 2030 strategy calls for expanding its RNAi pipeline across metabolic, cardiovascular, and neurological diseases, and AI-driven sequence optimization could meaningfully compress the discovery timeline for each new program.
Chinese Biotechs Are No Longer Selling Cheap
What Happened: BioSpace reported that deal dynamics between Chinese biotechs and global pharma companies are changing fast. Chinese companies are no longer a “bargain pool” and are commanding higher upfront payments.
What Changed
The shift reflects three converging dynamics. First, the clinical data quality from Chinese biotechs has reached global standards. Merck’s sac-TMT (Kelun-Biotech) cut progression risk by 65% in first-line lung cancer. Akeso’s ivonescimab became the first Chinese drug in the ASCO plenary in 61 years. Hengrui presented 90-plus studies at ASCO. These are not early-stage, unvalidated assets—they are clinical programs with registrational-quality data that perform at the highest level.
Second, multiple Western buyers are now competing for the best Chinese assets, which naturally drives up prices. When only one or two Western companies were actively licensing from China, the licensors had limited negotiating leverage. Now BMS, Pfizer, Lilly, Merck, GSK, and AbbVie are all competing for Chinese clinical-stage programs, creating an auction dynamic that favors the sellers.
Third, Chinese companies are structuring differently. Rather than licensing individual assets, they are pursuing broader platform deals. BMS/Hengrui covers 13 programs. Pfizer/Innovent covers 12 programs. Lilly/Haisco covers five programs. These portfolio-level transactions give the Chinese licensors more total value while giving Western buyers diversification across multiple shots on goal.
The implication for the industry is clear. The era of acquiring high-quality Chinese clinical assets at modest upfronts is ending. Companies that moved early—Merck with Kelun-Biotech, Lilly with Hengrui via Kailera—captured value at prices that may not be available to later entrants. The COINS Act debate adds a layer of uncertainty: if outbound capital restrictions are enacted, the supply of licensable Chinese assets could tighten further, driving premiums even higher for the deals that do get done.
The premium shift also creates a feedback loop that strengthens the Chinese biotech ecosystem. Higher upfront payments provide Chinese companies with more capital to invest in next-generation programs, which produces better clinical data, which commands higher premiums in the next deal cycle. The Chinese pharmaceutical industry is building the flywheel that the U.S. biotech industry built over the past three decades—clinical success funding more ambitious R&D, which funds more clinical success. The West-to-China licensing pipeline is not a temporary arbitrage opportunity. It is becoming a permanent feature of the global pharmaceutical landscape.
Biogen Gets Breakthrough Therapy Designation for SMA Drug
What Happened: Biogen received FDA Breakthrough Therapy designation for salanersen, an investigational antisense oligonucleotide for spinal muscular atrophy.
Why This Matters: Biogen already markets Spinraza for SMA but has faced competition from Novartis’s Zolgensma (one-time gene therapy) and Roche’s Evrysdi (daily oral). The SMA treatment landscape has evolved significantly since Spinraza’s 2016 approval—patients now have three mechanistically distinct options, and each subsequent entrant has taken share. A next-generation SMA treatment that demonstrates substantial improvement over existing therapies—the standard the FDA requires for Breakthrough designation—could reinvigorate Biogen’s neuroscience franchise at a time when the company is navigating the post-Leqembi landscape and restructuring its pipeline around neurology and rare disease.
Salanersen is an antisense oligonucleotide, the same modality as Spinraza, but designed to address limitations of the first-generation treatment. The Breakthrough designation provides more intensive FDA guidance, rolling review eligibility, and potentially expedited review, giving salanersen a faster path to market than a standard development timeline would allow. For Biogen, which has bet heavily on neuroscience as its core therapeutic franchise, a Breakthrough designation in SMA reinforces the company’s commitment to the neurological disease space even as it evaluates strategic options for its broader portfolio.
Strategic Themes
1. The Biotech IPO Window Is Open and Producing Increasingly Large Debuts
$475 million for Parabilis. $625 million for Kailera. $3.2 billion-plus in total 2026 proceeds. Five companies IPO-ing after raising $700 million or more privately. The IPO market is not just open—it is producing the largest biotech debuts in years. The quality of the companies going public has shifted too: they are arriving with validated platforms, existing pharma partnerships, and substantial private capital already invested. This is a healthy IPO cycle driven by genuine scientific progress and commercial demand, not speculative enthusiasm.
2. Schwan’s “Blackmail” Comment Opens a New Chapter in the Tariff Debate
A sitting chairman of one of the world’s largest pharmaceutical companies called the MFN framework blackmail in a public interview. This is not an anonymous source. It is not an industry lobbyist. It is the chairman of Roche. The comment gives permission—and cover—for other executives to speak more candidly about a policy framework that the entire industry has accepted publicly while resenting privately. Whether this changes the political dynamic is uncertain, but it changes the public conversation.
3. Chinese Biotech Premium Shift Signals Market Maturation, Not a Bubble
Chinese biotechs commanding higher upfronts is not a sign of overheating—it is a sign of maturation. The clinical data quality justifies higher prices. The competition among Western buyers creates market-clearing premiums. And the shift toward platform deals (13 programs, 12 programs, five programs) reflects a structural change in how Chinese assets are transacted. The China licensing market in 2026 bears little resemblance to the market in 2023. The assets are better. The prices reflect it.
4. AI Drug Discovery Is Fragmenting into Specialized Platforms
The Alnylam/Inceptive deal reinforces that AI in pharma is not converging toward a single platform—it is fragmenting into specialized tools matched to specific problems. RNA sequence optimization, protein structure prediction, recombinase design, and broad workflow AI are distinct applications requiring distinct platforms. The companies capturing the most value from AI are the ones making targeted platform choices rather than adopting AI generically.
Frequently Asked Questions
What is the Parabilis IPO?
Up to $475 million, which would be the year’s second-largest biotech IPO behind Kailera ($625 million). Parabilis develops Antibody-Helicon Conjugates and has an existing Regeneron partnership. The company raised $700 million-plus in private funding before filing.
What did the Roche chairman say?
Severin Schwan called U.S. tariff policies “blackmail” and said protectionism by the U.S. and China was Roche’s biggest geopolitical concern. His comments are the most direct public criticism of the MFN framework by a major pharma executive this year. All 17 targeted companies have signed MFN deals.
What is the Alnylam/Inceptive deal?
A strategic AI collaboration to accelerate RNAi discovery. Inceptive’s AI platform optimizes siRNA sequence design, compressing the identification of lead candidates from months to days. Part of Alnylam’s Alnylam 2030 strategy.
Are Chinese biotechs more expensive now?
Yes. BioSpace reported that Chinese companies are commanding higher upfront payments and are no longer a “bargain pool.” The shift reflects improved clinical data quality, competition among multiple Western buyers, and a move toward broader platform deals.
What is the Biogen SMA news?
FDA Breakthrough Therapy designation for salanersen, an antisense oligonucleotide for spinal muscular atrophy. The designation recognizes preliminary evidence of substantial improvement over existing therapies and provides a potentially expedited regulatory path.
What conferences are coming up?
ADA 2026 (GLP-1/obesity data) this month. BIO International Convention June 22 to 25 in San Diego. Medicare GLP-1 Bridge launches July 1.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
IPO Wave Health Check. We analyze why $475M Parabilis terms signal the IPO window remains wide open, compile the 2026 IPO scorecard across all biotech debuts, and assess what the $700M+ private funding threshold means for the quality of companies reaching public markets.
AI Drug Discovery Ecosystem Map. We map the full AI drug discovery landscape across Anthropic, Isomorphic, Profluent, Inceptive, and Recursion—how each platform serves a different pharma need, which partnerships are producing the most value, and where the next wave of AI deals is likely to land.
China Licensing Premium Shift. We analyze why Chinese biotechs are commanding higher premiums, how the competitive dynamics among Western buyers have shifted since 2023, and what the premium trend means for deal economics and the COINS Act debate.
Plus: Roche MFN “blackmail” implications, Biogen SMA Breakthrough assessment, Revolution filing watch, and the updated catalyst calendar through H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
